Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study

Conclusion: The combined use of TACE and sorafenib is generally well tolerated and could significantly increase OS of patients with unresectable HCC.

Source: Journal of Cancer - June 13, 2019 Category: Cancer & Oncology Authors: Baosheng Ren, Wansheng Wang, Jian Shen, Wanci Li, Caifang Ni, Xiaoli Zhu Tags: Research Paper Source Type: research